Alzheimer's Disease
Combination adrenergic activator improves several cognitive domains in patients with AD, PD
CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.
FDA grants breakthrough device designation to blood-based Alzheimer’s diagnostic assay
The FDA has granted breakthrough device designation to a phospho-tau 217 blood-based biomarker to assist in the diagnosis of Alzheimer’s disease, according to the manufacturer.
Quanterix announces collaboration with health care groups to expand access to AD testing
Quanterix Corp. has announced collaborations with several health systems with the goal of improving and simplifying Alzheimer’s disease diagnosis by expanding access to blood biomarker assays.
Treatment with acetylcholinesterase inhibitors for Alzheimer’s may reduce risk for AMD
Acetylcholinesterase inhibitors used to treat Alzheimer’s disease may also reduce the risk for developing age-related macular degeneration, according to a cohort study of older veterans published in JAMA Ophthalmology.
Phase 3 study of agitation drug fails to achieve primary efficacy endpoint
Otsuka has announced that a phase 3 clinical trial of AVP-786, a combination therapy to treat agitation associated with dementia due to Alzheimer’s disease, failed to achieve its primary endpoints.
Biopharma firm raises $30M to advance neuro, derm tyrosine kinase 2 inhibitors
An Indianapolis-area biopharmaceutical company announced it has raised $30 million in Series B financing to advance investigational tyrosine kinase 2 inhibitors for multiple sclerosis as well as dermatologic conditions.
Biotherapeutic company raises $120M to advance drug-resistant epilepsy treatment
A biotherapeutics company has raised $120 million to advance its pipeline of cell therapies, including a lead investigational regenerative neural cell therapy candidate to treat drug-resistant mesial temporal lobe epilepsy.
Diabetes management program in primary care reduces risk for dementia
A program geared toward diabetes management in the primary care setting helped to reduce patients’ risk for dementia — including Alzheimer’s disease — according to researchers.
Silo Pharma announces roster of drugs in development for mental health, chronic pain
Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.
Biogen announces discontinuation of Aduhelm
Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance Leqembi.